Pirfenidone is an anti-inflammatory and anti-fibrotic drug that has shown efficacy in lung and kidney fibrosis. Because inflammation and fibrosis have been linked to the progression of osteoarthritis, we investigated the effects of oral Pirfenidone in a mouse model of cartilage injury, which results in chronic inflammation and joint-wide fibrosis in mice that lack hyaluronan synthase 1 (Has1 À/À
The cellular response mechanisms that underlie intrinsic cartilage and subchondral bone repair after joint injury are poorly understood, although it is now clear that they cannot be delineated under the simplistic paradigm of a balance of matrix anabolism versus catabolism. [1] [2] [3] [4] Therefore, the discovery of new targetable disease mechanisms is essential to the design of effective biological therapies to complement existing strategies for osteoarthritis (OA) prevention in the clinic. With respect to post-traumatic OA, the cellular reaction to joint tissue injury can be viewed as a classical "wound-healing" response, involving a balance between "inflammatory/fibrotic" and "chondrogenic/osteogenic" pathways in the injured joint environment.
Within the classic wound healing response, tissue injury results in cell proliferation, differentiation, extracellular matrix production and remodeling; alterations in this process can lead to uncontrolled deposition of granulation tissue, fibrosis, and scar formation. These phenomena are well described in dermal wounds 5 and internal organs, like the lung and liver, [6] [7] [8] [9] [10] where recurrent inflammation may lead to chronic fibrosis and deterioration of function. In organ fibrosis, various anti-fibrotic drugs have shown clinical promise in reducing the formation of scars and halting, or at least slowing the progression of, functional loss. 11 Strategies used in organ fibrosis may therefore hold promise for applications in the injured joint, where the processes of inflammation and fibrosis are also hallmarks of OA development. Substantial evidence for the activation of collagen synthesis and fibrotic remodeling in human OA cartilage has recently been described in at least eight independent genome-wide analysis studies. 12 There is also accumulating evidence from human OA studies for scarring responses in bone, 13, 14 meniscus and cartilage, 15 as well as joint capsule and synovium, 16 with similar findings in animal models of OA. [17] [18] [19] These suggested that fibrotic scarring of joint tissues represents a potentially important drug target for OA therapy. Anti-fibrotics that are commonly used for lung and kidney fibrosis have shown both safety and efficacy with extended use. 11, 20 Prominent among these is 5-methyl-1-phenyl-2-(1H)-pyridone or pirfenidone (PFD), which has been evaluated in animal models and used clinically in a wide range of inflammatory or fibrotic conditions-including idiopathic pulmonary fibrosis, 21 primary sclerosing cholangitis, 22 chronic hepatitis C, 23 myelofibrosis, 24 neurofibromatosis, 25 fibrotic disorders of cardiac 26 and renal 27 origin, and corneal scarring 28 -and is currently in clinical trials for scleroderma. 29 It has been suggested that the anti-fibrotic action of PFD stems from suppression of TGF-b1 driven collagen type I expression, and the underlying mechanism is under active study. 30, 31 For example, PFD inhibits the non-canonical hedgehog (Hh) pathway by shortening the half-life of endogenous full-length gliomaassociated oncogene homolog 2 (GLI2), a transcription factor, by more than threefold, and thereby reduces Hh/TGF-b signaling and expression of collagen type I. 32 PFD has also been shown to reduce IL-1b-induced hyaluronan production in orbital fibroblasts. 33 PFD has shown pain relief in RA 34 and may also be able to block nitric oxide release in articular chondrocytes, 35 but PFD has not yet been tested in vivo against posttraumatic OA.
Similarities between the chronic inflammation and wide-spread joint fibrosis in this cartilage injury model and the inflammatory events that lead to fibrosis in other organs 36, 37 have therefore led us to consider PFD as a possible disease-modifying drug. Accordingly, in this study we use gene expression, histology, gross pathology, and micro-computed tomography (mCT) to evaluate the effects of PFD after cartilage injury in the murine joint. Additionally, among the numerous genes linked to the tissue injury response, hyaluronan synthase 1 (Has1) has been linked to abnormal wound healing and hypertrophy in the skin, muscle, and lungs, 8, [38] [39] [40] as well as the synovial membranes of OA patients 41 and murine joints after cartilage injury. 42 Therefore, we also use homozygous Has1 knockout (Has1
) mice, which show abnormal wound healing 38 and chronic inflammation and fibrosis with joint injury, 42 to examine whether PFD can alter the outcome in the absence of Has1.
METHODS

Cartilage Injury Model
Wild-type and Has1 À/À male C57Bl/6 mice (skeletally mature, 11-12 weeks old, 28.3 AE 2.5 g and 23.9 AE 1.4 g, respectively) from in-house colonies were used under approval of the Rush University Institutional Animal Care and Use Committee. Mice were housed in groups of 4-5 males, which were treated with no surgery (na€ve), sham operation, or cartilage injury, without or with PFD; individual mice were then assigned toward experimental outcomes as needed. With a mouse under anesthesia, cartilage injury to the patellar groove of the right knee was performed as previously described. 42 Briefly, after medial parapatellar arthrotomy, femoral groove cartilage was debrided from a rectangular surface ($2-mm wide Â 4-mm long) without penetrating the subchondral bone. Sham surgery included all steps, except cartilage debridement, and na€ve mice did not receive anesthetic or surgery. All mice were maintained at cage activity with food and water provided ad libitum until sacrifice after 4 weeks.
Oral Dosing With PFD
All PFD groups were switched from the standard chow to PFD chow (5 mg PFD per g chow, Envigo, formerly Harlan, Madison, WI) at 12 weeks for na€ve mice and 3 days after surgery for sham and injury groups. PFD chow was weighed at least twice weekly to monitor intake of the drug. Using an estimated absorption efficiency of $20% 43 42, 44 and mouse numbers in experimental groups are given (Table S-1) with experiment timelines (Fig. S-1 ). Treatments were the same within a cage, and mice within each cage were randomly assigned to experimental outcomes as described below.
Macroscopic Joint Imaging and Histology
Joint wide pathology (n ¼ 3) was assessed in na€ve and operated joints, without and with PFD treatment, as previously described 42, 44 for all experimental groups. These joints were then reserved for subsequent mCT, as described further in the Methods below.
For histology (n ¼ 3), skin and muscle were removed, joints decalcified, processed, and embedded as described. 42 Specimens were sectioned (6-mm thick) with sagittal sections 1-60, 61-120, and 121-190 spanning the medial, central, and lateral regions, respectively. 44 Sections from medial compartment, joint midline, and lateral compartment were stained with Safranin-O or biotinylated TNF-stimulated gene 6 protein (bTSG6) to localize sulfated glycosaminoglycans and hyaluronan, respectively. 42 Histology was used in combination with macro-images to evaluate structural alterations in multiple tissue types adjacent to the injury and throughout the joint.
Quantitative PCR (qPCR) for Selected Genes and Gene Arrays
For gene expression in whole joints, hind legs were harvested immediately after sacrifice and whole knee joints isolated as previously described 42 which was then used to estimate tissue mineral density (TMD), bone volume fraction (BV/TV), and trabecular bone parameters of number (Tb.N), thickness (Tb.Th), and spacing (Tb.Sp). Cortical bone volumes of interest were similarly segmented for estimation of cortical bone parameters.
Statistical Analyses
Analysis of mCT and gene expression data was performed with software (Matlab R2016a), and all data are presented as mean AE standard deviation, unless otherwise indicated. Normality of the data sets were tested with Kolmogorov-Smirnov test prior to election of a parametric or non-parametric test. Nonparametric analyses were therefore performed in cases where data sets were found to be not normally distributed. The experiment-wide significance level was a ¼ 0.05. Two-tailed Student's t test were used to compare mouse weights and chow intake. For gene expression, one-way analysis of variance (ANOVA) was used to compare Gapdh Ct values across experimental groups to confirm selection of a housekeeping gene that did not vary with treatment. Because most sets of DCt values were found to not fall under the normality assumption, nonparametric tests were used to compare between experimental groups. Therefore, KruskalWallis Test was used first to determine the effect of surgery among the na€ve, sham, and injury groups, separately for wild-type and Has1
À/À groups, and then to test among SN, SP, IN, and IP groups, to determine the effects of cartilage injury and PFD dosing. Post hoc comparisons using a DunnSidak correction were used to identify significantly different experimental groups.
For the normally distributed bone parameters from mCT, two-way ANOVA was used to evaluate the effects of surgery (na€ve, sham, cartilage injury) and drug administration (none, PFD). For statistically significant effects, post hoc pair-wise comparisons were performed with Tukey's honest significant difference test.
RESULTS
Wild-type and Has1
À/À mice were operated on as described previously 42 and evaluated 4 weeks after injury with joint surface pathology, distal femur mCT imaging, gene expression, and histology ( Fig. S-1 
Joint Pathology 28 Days After Intra-Articular Cartilage Injury in Wild-Type and Has1
À/À Mice As previously described in this model, 42 a fibrotic response after debridement of patellar groove cartilage was observed, specifically as an excessive deposition of fibrous extracellular matrix, at both trochlear ridges near the injury site. This fibrotic tissue deposition was generally exacerbated in the absence of Has1 (Fig. 1A) . mCT of these same specimens (Fig. 1B) showed bony erosion and pitting co-localized with the fibrotic deposits observed with joint surface photography. No fibrosis or bony erosion was detected in age-matched na€ve joints.
Effect of Pirfenidone on Joint Fibrosis and Bone Pitting After Cartilage Injury
The same imaging methods showed that PFD dosing essentially eliminated the fibrotic reaction in both genotypes ( Fig. 1C) and also blocked the bone pitting near the cartilage injury site and the bone erosion at the periarticular margins (Fig. 1D ). Despite the qualitatively protective effects of PFD against fibrosis and bone pitting in both genotypes, PFD dosing of injured wild-type mice had no detectable effect on any trabecular bone parameters within the metaphysis or epiphysis ( Fig. S-2 ) because surgery effects dominated (p < 0.05, Table 1 and Fig. 2 ). For example, cartilage injury resulted in a 41% decrease in BV/TV in wild-type metaphysis in both dosed (p < 0.01) and non-dosed (p < 0.05) mice.
In contrast, PFD dosing was the dominant effect on Has1 À/À bone parameters, while the injury effect on BV/TV or any other trabecular bone parameter was not significant (Table 1 ). In the metaphysis of injured Has1 À/À mice, PFD dosing slightly increased BV/TV (p < 0.05) and Tb.N (p < 0.05) and reduced Tb.Sp (p < 0.01) relative to non-dosed injured mice (Table 1) . Notably, na€ve Has1 À/À mice showed reduced trabecular bone density and bone parameters that were significantly different from na€ve wild-type, including metaphyseal (p < 0.001) and epiphyseal (p < 0.01) BV/TV, metaphyseal (p < 0.01) and epiphyseal (p < 0.001) Tb.Th, metaphyseal Tb.Sp (p < 0.001), and metaphyseal Tb.N (p < 0.001). Trabecular bone tissue mineral densities (Table S-3) and cortical bone parameters (Table S- 4) showed no significant differences between groups (Table S- 5) . It therefore appears that PFD treatment for 25 days does not alter bone parameters in any treatment group of wild-type mice but leads to a partial normalization of the low values for BV/TV and Tb.N in the injured Has1 À/À group.
Effects of PFD Dosing on Injury-Induced Changes in Gene Expression
Given the apparently protective effects of PFD dosing against fibrosis and bone pitting at the injury site in both genotypes (Fig. 1) , we examined the expression of fibrosis and NF-kB pathway genes, as well as selected matrix genes, in the combined joint tissues harvested between the tibial and femoral growth plates. PFD caused a significant activation (p < 0.05) of 30 genes in wild-type (Tables 2, S-6 , and S-7) whereas the same comparison for Has1 À/À mice (Tables 3, S showed activation (p < 0.05) of only seven genes. Two genes (Il4, Itgb8) were significantly upregulated by PFD in both phenotypes, but to a much greater extent in wild-type than in Has1 À/À mice. In wild-type mice, the activations ranged from 3.9-fold (Snai1) to 2876-fold (Timp1), and in Has1 À/À mice from 2.3-fold (Vcam1) to 18.9-fold (Fasl). Assays for matrix-related genes (Table S-10) showed high variability and no injury or PFD effects that reached statistical significance.
The genotype-specific effects of PFD at 28 days (Tables 2 vs. 3) result primarily from a marked genotypic difference in the effect of injury itself on expression levels. For wild-type mice, the expression levels (relative to age-matched na€ve) after injury were either markedly (e.g., Timp1, Mmp1a, Tgfbr2, Irf1, etc.) or modestly (e.g., Itgb6, Serpine1, Itgb8, etc.) reduced at 28 days, (except for Mmp3 which was moderately activated), confirming earlier data with this model. 42 In contrast, for Has1 À/À mice, expression of most of those genes was not reduced but similar to na€ve levels at 28 days after injury, except for Timp1 and Mmp3, which were markedly activated even in Has1 À/À . Therefore for wild-type mice, the response to injury was a broad reduction in gene expression at 28 days, and this effect of injury was prevented by PFD dosing. In contrast, for Has1 À/À mice, the injury did not broadly inhibit expression at 28 days and the PFD was largely without effect.
Effect of PFD Dosing in Sham-Operated Joints
To determine the extent to which the bone pitting in both genotypes (Fig. 1) , loss of BV/TV in wild-type mice (Fig. 2) and genotype-specific changes in gene expression with and without PFD at 28 days (Tables 2  and 3 ) require intra-articular injury (such as cartilage debridement), we examined the effects of sham injury on these parameters. Firstly, unlike after cartilage injury, there was no evidence for an effect of sham on bone pitting in either genotype, and there was no loss of BV/TV in wild-type mice. Secondly, fibrosis and NF-kB pathway gene expression analysis (Tables S-6 to S-9) showed that for many genes (27 for wild-type and 35 for Has1
) the transcript abundance at 28 days after sham-injury was higher than after intraarticular injury (p < 0.05), consistent with a responsiveness of these genes to both types of injury. Nonetheless, it appears that the process that markedly À/À mice at 28 days after cartilage injury (triangles) or sham (squares) operation, as compared to na€ve (circles). WT and Has1 À/À mice were either left without drug (white and light gray shapes, respectively) or treated with pirfenidone (PFD) starting 3 days after operation (medium and dark gray shapes, respectively). Mean (black bars) AE standard deviation (black lines) are indicated for each group. Twoway analysis of variance was performed, taking surgery and PFD treatment as main effects. Significant post hoc differences were found between surgery types with no dosing (solid lines above data points), between surgery types with PFD dosing (solid lines below data points), and within a surgery group without and with drug (dashed lines above data points). Figure 2 .
PIRFENIDONE REDUCES POST-INJURY JOINT FIBROSIS
369
reduces expression of 36 genes between day 12 and day 28 in injured wild-type mice 42 is not active in sham-operated wild-type joints over this period. However, none of the genes that were activated by PFD dosing at day 28 after intra-articular injury (30 for wild-type, Table 2 , and seven for Has1 Table 3) were affected by PFD dosing after sham injury (Table S- 11 ), although such a difference might be masked by the gene-activating effect of the sham injury itself. Lastly, in Has1 À/À mice, BV/TV (p < 0.05, p < 0.05) and Tb.Th (p < 0.01, p < 0.001) in the metaphysis and epiphysis, respectively, were enhanced by PFD dosing after both cartilage and sham injury, in general agreement with its effects on the intrinsically low values in Has1 À/À mice (Fig. 2) .
Altered Histological Staining of sGAGs and Hyaluronan After Joint Injury and PFD Dosing
Multiple Safranin-O stained sections from na€ve and injured joints of non-dosed wild-type mice (Fig. 3) , showed a marked injury-induced enhancement of staining in the femoral growth plate. With PFD dosing in injured mice, the enhanced growth plate staining was even greater and was accompanied by periosteal chondrogenesis on the lateral aspect. Enhanced growth plate staining in dosed mice was consistent with the loss of hyaluronan staining observed, indicative of aggrecan deposition and masking of hyaluronan binding sites. A similar response to PFD dosing was seen in injured Has1 À/À joints (Fig. 4) , with periosteal staining on the medial aspect, indicating that the excessive fibrotic scarring response in non-dosed Has1À/À joints (Figs. 2 and 4 ) that was also previously observed 42 was modified to a chondrogenic response with PFD dosing.
Safranin-O staining of sham-injured joints (Fig. 5 ) from non-dosed wild-type mice showed weak staining in the growth plate, which was markedly enhanced by PFD dosing, but no periosteal responses were observed. This observation was also supported by the Arrays for fibrosis and NF-kB pathway genes were used to determine gene expression in the joints of injured hyaluronan synthase 1 knockout (Has1 loss of hyaluronan staining. However, non-dosed Has1 À/À mice showed an enhanced fibrotic scarring response in the areas of soft tissue damage made during sham injury (Fig. 5) , and this response was essentially absent in PFD-dosed mice, consistent with an anti-fibrotic effect of PFD on the soft tissue wounds of the sham surgery.
DISCUSSION
Post-traumatic OA is widely studied in clinical and animal model research to describe pathological remodeling in joint tissues after different types of injuries. 45, 46 The severe murine cartilage injury used here had shown fibrotic, chondrogenic, and bone remodeling responses. 42 Toward efforts to identify novel therapeutic targets for different cellular response networks, we have here examined efficacy of the anti-fibrotic and anti-inflammatory drug PFD during the post-injury joint tissue regeneration response.
The Relationship Between Has1, Fibrosis, and Bone Metabolism Several targetable pathways were suggested by the finding that Has1 À/À mice showed a markedly exacerbated fibrotic pathology and this was accompanied by prolonged activation (relative to wild-type) of hyaluronan network genes (Has1, Tnfaip6), matrix genes (Acan, Col1a1, Col3a1) and genes related to the IL-17/ IL-6 axis, extracellular matrix remodeling, and apoptosis. 42 Further evaluation of this data has shown that, early in the response (day 12), the absolute expression of nine genes (Irf1, Stat3, Stat5b, Nfkb2, Nfkbia, Icam1, Csfr2b, Plau, Xiap) was inhibited greater than fivefold in Has1 À/À mice, 42 raising the possibility that their low expression on day 12 might also be related to the exacerbated pathology at day 28. Notably, these nine genes are associated with NF-kB signaling rather than fibrosis, suggesting that Has1 À/À joint tissues are less active in inflammation-related signaling thru these factors at day 12. 42 It appears relevant that Irf1, in addition to its role in Toll-like receptor-mediated Stat activation, 47 has been implicated in the maturation and activity of osteoclasts and osteoblasts. 48 Indeed, an interplay between Has1, Irf1 expression, and bone metabolism might explain the low BV/TV, Tb.Th, and Tb.N values found in na€ve Has1 À/À mice (Fig. 2) and also the apparent role of Has1 in osteophyte formation. 49 The finding that na€ve Has1 À/À mice had reduced trabecular bone quality, which was similar to injured 
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wild-type values but not further diminished by injury, is consistent with the presence of injury-labile bone fraction which requires Has1 for its maintenance. Such putative Has1-dependent bone metabolism might be a consequence of the apparent role of Has1 in bone marrow mesenchymal progenitor activity. 50 Further, the widely variable expression profile of Nfkb2 in postinjury Has1 À/À mice (78-fold higher, 49-fold lower, and 34-fold higher than wild-type at 3, 12, and 28 days, respectively 42 ) would also appear to link Has1 to control of post-injury bone turnover thru modulation of osteoclastic activity. 51, 52 Prochondrogenic, Anti-Fibrotic, and Bone-Protective Effects of PFD After Injury PFD dosing for 25 days enhanced post-injury aggrecan deposition in the growth plate and perichondrial regions adjacent to the cartilage damage in both genotypes, thus appearing to convert the collagen-rich and proteoglycan-poor repair tissues in Has1 À/À joints (Fig. 4) into the cartilaginous repair tissues seen in wild-type joints (Fig. 3) . These results are supported by the known role of PFD in reducing collagen type 1 synthesis. 30, 31 However, the expression of classic chondrogenic genes (Acan and Col2a1) at day 28 was either unaffected or moderately inhibited by PFD dosing (Table S-10 ). This apparent anomaly would be explained if the PFD acted indirectly by blocking catabolism of aggrecan by aggrecanases (such as Adamts9) and collagen by collagenases (such as Mmp1a). Such an effect on metalloproteinases has been previously observed with PFD-induced suppression of MMP-2 in fibrotic liver. 31 Indeed, the expression of MMP inhibitors Timp3 and Timp1 was markedly higher in PFD-dosed mice of both genotypes (Table S-9), further supporting the explanation that PFD acts in the joint to block catabolism of cartilaginous tissues. Additionally, the suppression of the GLI2/Hh axis by PFD may also affect the injury response of the epiphyseal growth plate ECM, as evidenced by the increase in staining after PFD dosing being greater with cartilage injury than with sham operation. Although PFD consistently increases the Safranin-O staining of growth plate cartilage, it is of note that there remain differences in staining between individual mice without PFD treatment (Figs. 3-5 ), most likely due to variations between animals in the completion of epiphyseal bone calcification processes. 53 It may also be relevant that the fibrotic tissue deposits around the cartilage injury site at 7 days stain positively with Safranin-O by 28 days, typical of a chondrophyte-like outgrowth. 42 These chondrophytic deposits are associated with the pitting seen in the underlying cortical bone (Fig. 1) . Therefore, if PFD reduces the deposition of fibrotic tissues during the proliferative phase, remodeling of that temporary matrix into chondrophytic tissue is likewise reduced, a reduction that would be reflected in both the lower Col2a1 expression observed and the prevention of cortical bone loss at the site of injury. The corresponding PFD-driven depression of pro-fibrotic genes in the proliferative phase is consistent with reports that PFD reduces collagen expression 30, 31 and blocks fibroblast proliferation and migration by destabilizing GLI2 and suppressing both TGF-b and Hh signaling pathways. 32 Moreover, inhibition of the GLI2/Hh axis by PFD 54 might underlie the pro-chondrogenic effect in both genotypes (Figs. 3-5 ) on the growth plate ECM 55, 56 and the anabolic effect on the subchondral bone. 57 However, these direct effects of PFD during early postinjury time points could not be measured with the current study design and remain to be examined in further studies.
Has1 À/À mice also showed an enhanced fibrotic scarring response, relative to wild-type, in the areas of soft tissue damage made during sham injury (Fig. 5) . This response was essentially absent in PFD-dosed mice after sham surgery, consistent with an antifibrotic effect of PFD on the soft tissue wounds. 58, 59 PFD blocking of bone pitting and erosion near the injury site in both genotypes (Fig. 1B vs. D) might be explained by the PFD-stimulated expression of genes which have been implicated in bone turnover, such as Irf1 48 and Nfkb2. 51, 52 Such a mechanism for PFDmediated bone protection appears reasonable since both Irf1 and Nfkb2 have been shown to prevent excessive osteoclastic activity in mutant mice. 48, 51, 52 Enhanced expression of Timp1, Timp3, Irf1, and Nfkb2 might also explain the pro-chondrogenic and bone-protective effects of PFD in this model. However, the anti-fibrotic effects observed cannot be explained by inhibition of the classical markers (Col1a1, Timp1, Mmp2), since they were increased with PFD rather than decreased, as shown previously in animal models of lung, liver, kidney, and heart fibrosis. 60 In this regard, it is important to note that in the current work we have evaluated PFD on gene expression in both a different organ system and within a mixed tissue pool including cartilage/bone, menisci, ligaments and synovium, meaning that the effects cannot be attributed to the response of any single tissue or cell type. Overall, the effects were associated with an apparent increase in expression (relative to no PFD dosing) at 28 days after injury of almost all 164 genes (inclusive of NF-kB and fibrosis arrays and extracellular matrix genes) examined in both genotypes (154/164 in wild-type, 135/164 in Has1 À/À ), with the effects reaching statistical significance in 36 genes in wild-type and 7 genes in Has1 À/À . Examination of the genes that were significantly upregulated in injured wild-type joints with PFD indicates that the anti-fibrotic effect might be exerted thru activation of genes involved in many processes including the TGF-b signaling genes Smad6, Tgfb2, and Tgfbr2. Notably, the 21-fold activated 
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expression of Smad6 (Table 2) would be expected to exert a significant anti-fibrotic effect in fibroblastic tissues of the joint. 61 
Therapeutic Potential of PFD in Post-Injury Musculoskeletal Medicine
This study has shown that the anti-fibrotic drug PFD reduced bone loss and fibrotic tissue deposition after cartilage injury in young male mice of both wild-type and Has1-null genotypes. Female mice were not utilized in this study because the estrous cycle could have a significant effect on the acute bone and innate immune response to injury and PFD treatment; however, the potential for PFD in reducing bone loss after joint injury warrants additional study in how the effects of PFD may be altered by hormonal variation (e.g., bone turnover rates 62 ). Additionally, younger mice were utilized in this study of cartilage injury because of the prevalence of joint injury in younger adults in both civilian and military populations. The cascade of events that lead to the development of posttraumatic OA after a known injury event is also a readily targetable disease state for pharmaceutical intervention.
Future work is also needed to include a time course of PFD effects at the tissue and cell specific level (cartilage, subchondral bone, meniscus, synovium), as well as to identify an optimal time frame for the initiation and duration of drug administration. Such information may contribute to development of adjunct pharmacological therapies to enhance cell-based or surgical joint tissue repair strategies. Since, at the morphological level, it appears that PFD influences the pathway normally regulated by Has1 À/À to avoid excessive scarring, more detailed information on the mechanism of action of Has1 À/À in the post-natal tissue regeneration response may be obtained by studying in vitro effects of PFD on regulatory pathways in relevant cell populations such as osteoblast, osteoclasts, chondroprogenitors, and synoviocytes.
PFD and other anti-fibrotic drugs 18 may also be able to supplement surgical and pharmaceutical interventions, 63 which individually have thus far been ineffective in preventing OA. Success rates of surgical interventions have shown arthroscopy to be ineffective in preventing OA. 64 Furthermore, anti-inflammatory disease-modifying OA drugs, although often effective against inflammation and pain in the short term, 65 have shown some adverse effects 66 and little to no successful long-term clinical results. 67 Among those, dexamethasone has shown reduced inflammation in a post-traumatic OA model 68 as well as effectiveness against the inflammation that precipitates pulmonary fibrosis. 69, 70 Likewise, some bisphosphonates have shown some promise for chondroprotection in animal models. [71] [72] [73] Naproxen, while effective in short-term pain treatment, may interfere with osteochondral repair in a mechanism involving enhanced expression of GLI2, 57 which is suppressed by the anti-fibrotic actions of PFD. In addition to suppression of GLI2 by PFD, other anti-fibrotic drugs could target lysophosphatidic acid, which has also been shown to block collagen type 1 production by chondrocytes and stromal cells in vitro. 18 In conclusion, the chondroprotective potential of PFD shown in this cartilage injury model in young mice indicates that further studies of PFD's efficacy in older animals and with other models of OA are warranted. Cell and tissue specific effects of PFD should also be examined, in addition to investigation of the role that Has1 and hyaluronan metabolism may play in the joint injury response. Effective therapies for preventing or reversing OA progression after injury may well depend on a combination of various pharmaceutical, physical, and other therapies, applied in coordination with the progression of wound healing processes within the joint.
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